10 Best Mid Cap Stocks to Buy According to Billionaires

6. Disc Medicine, Inc. (NASDAQ:IRON)

Number of Billionaire Holdings: 9

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious hematologic diseases by targeting red blood cell biology, particularly heme biosynthesis and iron homeostasis. Its lead candidate, bitopertin, is being developed for erythropoietic protoporphyria (EPP), which is a rare genetic disorder causing severe light sensitivity and liver complications.

In July 2025, the company held a positive pre-New Drug Application (NDA) meeting with the U.S. FDA, receiving strong alignment on its submission plans. Disc Medicine, Inc. (NASDAQ:IRON)  is now on track to submit the NDA for bitopertin in October 2025 through the FDA’s accelerated approval pathway, supported by existing clinical data. As there is currently no cure for EPP, and the only approved therapy offers indirect relief by stimulating melanin, bitopertin represents a potentially disease-modifying treatment that could fulfill a major unmet medical need.

Given its innovative pipeline and progress toward regulatory approval, IRON is emerging as one of the best mid-cap stocks in the biotech industry. Beyond bitopertin, the company is also advancing DISC-0974 for anemia in myelofibrosis and DISC-3405, both of which have shown encouraging early clinical results. To support its pipeline and regulatory milestones, the company has secured robust financing that extends its cash runway into 2027.

The upcoming NDA submission is a pivotal milestone for Disc Medicine, Inc. (NASDAQ:IRON), marking its transition from clinical development to the potential launch of its first commercial product. If approved, bitopertin could significantly improve the quality of life for EPP patients and establish the corporation as a leader in rare hematologic disease innovation.